Cashman Derek J, Kellogg Glen E
Department of Medicinal Chemistry and Institute for Structural Biology & Drug Discovery, School of Pharmacy, Virginia Commonwealth University, P.O. Box 980540, Richmond, Virginia 23219-0540, USA.
J Med Chem. 2004 Mar 11;47(6):1360-74. doi: 10.1021/jm030529h.
Anthracycline antibiotics such as doxorubicin and its analogues have been in common use as anticancer drugs for almost half a century. There has been intense interest in the DNA binding sequence specificity of these compounds in recent years, with the hope that a compound could be identified that could possibly modulate gene expression or exhibit reduced toxicity. To computationally analyze this phenomenon, we have constructed molecular models of 65 doxorubicin analogues and their complexes with eight distinct DNA octamer sequences. The HINT (Hydropathic INTeractions) program was utilized to describe binding, including differences in the functional group contributions as well as sequence selectivity. Of these 65 compounds, two compounds were calculated to have a selectivity (the calculated DeltaDeltaG(sel) between the sequence with the strongest binding and the second strongest binding sequence) greater than -0.75 kcal mol(-1) for one sequence over all others, 10 compounds were specific between -0.50 and -0.74 kcal mol(-1), 18 compounds were specific between -0.25 and -0.49 kcal mol(-1), and 35 compounds were virtually nonspecific with a DeltaDeltaG below -0.24 kcal mol(-1). Several compounds have been identified from this study that include features which may enhance sequence selectivity, including several with a halogen in lieu of the 4'-OH in the daunosamine sugar, one compound with a nonaromatic six-membered ring (pirarubicin) in place of the 4'-OH, and a compound with an aromatic ring in the vicinity of the C(14) region (zorubicin). Removal of the methoxy group at the C(4) position on the aglycone portion also appears to add potency and selectivity (idarubicin). Overall, efficient computational methods are presented that can be utilized to analyze the free energy of binding and sequence selectivity of both known and designed analogues of doxorubicin to identify future lead compounds for further experimental research.
蒽环类抗生素,如阿霉素及其类似物,作为抗癌药物已广泛使用了近半个世纪。近年来,人们对这些化合物与DNA结合的序列特异性产生了浓厚兴趣,希望能找到一种可以调节基因表达或降低毒性的化合物。为了通过计算分析这一现象,我们构建了65种阿霉素类似物及其与8种不同DNA八聚体序列复合物的分子模型。利用HINT(亲水性相互作用)程序来描述结合情况,包括官能团贡献的差异以及序列选择性。在这65种化合物中,计算得出有两种化合物对一种序列的选择性(最强结合序列与第二强结合序列之间计算得到的ΔΔG(sel))大于-0.75 kcal mol(-1),高于所有其他序列;10种化合物的选择性在-0.50至-0.74 kcal mol(-1)之间,具有特异性;18种化合物的选择性在-0.25至-0.49 kcal mol(-1)之间,具有特异性;35种化合物的ΔΔG低于-0.24 kcal mol(-1),几乎没有特异性。通过这项研究已鉴定出几种具有可能增强序列选择性特征的化合物,包括几种用卤素取代柔红糖胺糖中4'-OH的化合物、一种用非芳香六元环(吡柔比星)取代4'-OH的化合物,以及一种在C(14)区域附近有芳香环的化合物(表柔比星)。去除糖苷配基部分C(4)位的甲氧基似乎也能增加效力和选择性(伊达比星)。总体而言,本文介绍了有效的计算方法,可用于分析阿霉素已知和设计类似物的结合自由能和序列选择性,以确定未来用于进一步实验研究的先导化合物。